MF101: a multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms

Bibliography

• Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol 1996;87(2 Suppl):2S-15S
   PubMed Web of Science ®Google Scholar
• Hall JE. Neuroendocrine changes with reproductive aging in women. Semin Reprod Med 2007;25:344-51
   PubMed Web of Science ®Google Scholar
• Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397-428
   PubMed Web of Science ®Google Scholar
• Te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141-54
   PubMed Web of Science ®Google Scholar
• Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health organization collaborative study of neoplasia and steroid contraceptives. Am J Epidemiol 1998;148:1195-205
   PubMed Web of Science ®Google Scholar
• Wood JW. Fecundity and natural fertility in humans. Oxf Rev Reprod Biol 1989;11:61-109
   PubMedGoogle Scholar
• Walker ML, Herndon JG. Menopause in nonhuman primates? Biol Reprod 2008;79:398-406
   PubMed Web of Science ®Google Scholar
• Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975;55:699-706
   PubMed Web of Science ®Google Scholar
• Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008;15(4 Pt 1):603-12
   PubMed Web of Science ®Google Scholar
• Kok HS, van Asselt KM, van der Schouw YT, Genetic studies to identify genes underlying menopausal age. Hum Reprod Update 2005;11:483-93
   PubMed Web of Science ®Google Scholar
• Arias E, MacDorman MF, Strobino DM, Guyer B. Annual summary of vital statistics–2002. Pediatrics 2003;112(6 Pt 1):1215-30
   PubMed Web of Science ®Google Scholar
• Wallis J. A survey of reproductive parameters in the free-ranging chimpanzees of Gombe National Park. J Reprod Fertil Suppl 1997;109:297-307
   Google Scholar
• Margulis SW, Atsalis S, Bellem A, Wielebnowski N. Assessment of reproductive behavior and hormonal cycles in geriatric western lowland gorillas. Zoo Biol 2007;26:117-39
   PubMed Web of Science ®Google Scholar
• Bronikowski AM, Alberts SC, Altmann J, The aging baboon: comparative demography in a non-human primate. Proc Natl Acad Sci USA 2002;99:9591-5
   PubMed Web of Science ®Google Scholar
• Martin LJ, Carey KD, Comuzzie AG. Variation in menstrual cycle length and cessation of menstruation in captive raised baboons. Mech Ageing Dev 2003;124:865-71
   PubMed Web of Science ®Google Scholar
• Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. J Br Menopause Soc 2006;12(1):7-11
   PubMedGoogle Scholar
• Albertazzi P. A review of non-hormonal options for the relief of menopausal symptoms. Treat Endocrinol 2006;5:101-13
   PubMedGoogle Scholar
• Carpenter JS, Gilchrist JM, Chen K, Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause 2004;11:375-81
   PubMed Web of Science ®Google Scholar
• Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:332-7
   PubMed Web of Science ®Google Scholar
• Freedman RR. Core body temperature variation in symptomatic and asymptomatic postmenopausal women: brief report. Menopause 2002;9:399-401
   PubMed Web of Science ®Google Scholar
• Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-8
   PubMed Web of Science ®Google Scholar
• Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007;10:247-57
   PubMed Web of Science ®Google Scholar
• Molnar GW. Body temperatures during menopausal hot flashes. J Appl Physiol 1975;38:499-503
   PubMed Web of Science ®Google Scholar
• Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990;592:52-86
   PubMed Web of Science ®Google Scholar
• Koutsilieris M, Tolis G. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. Prostate 1983;4:569-77
   PubMed Web of Science ®Google Scholar
• Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc 2010;85:560-6
   PubMed Web of Science ®Google Scholar
• Rand KL, Otte JL, Flockhart D, Modeling hot flushes and quality of life in breast cancer survivors. Climacteric 2011;14:171-80
   PubMed Web of Science ®Google Scholar
• Aziz NA, Heyns CF. Evaluation of core and surface body temperatures, prevalence, onset, duration and severity of hot flashes in men after bilateral orchidectomy for prostate cancer. Int Braz J Urol 2008;34:15-20
   PubMed Web of Science ®Google Scholar
• Thurston RC, Christie IC, Matthews KA. Hot flashes and cardiac vagal control during women's daily lives. Menopause 2012;19:406-12
   PubMed Web of Science ®Google Scholar
• Hautamaki H, Piirila P, Haapalahti P, Cardiovascular autonomic responsiveness in postmenopausal women with and without hot flushes. Maturitas 2011;68:368-73
   PubMed Web of Science ®Google Scholar
• Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990;76:573-8
   PubMed Web of Science ®Google Scholar
• Dormire SL. The potential role of glucose transport changes in hot flash physiology: a hypothesis. Biol Res Nurs 2009;10:241-7
   PubMed Web of Science ®Google Scholar
• Sturdee DW. The menopausal hot flush–anything new? Maturitas 2008;60:42-9
   PubMed Web of Science ®Google Scholar
• Vilar-Gonzalez S, Perez-Rozos A, Cabanillas-Farpon R. Mechanism of hot flashes. Clin Transl Oncol 2011;13:143-7
   PubMed Web of Science ®Google Scholar
• Thurston RC, El Khoudary SR, Sutton-Tyrrell K, Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? findings from the Study of Women's Health Across the Nation. Menopause 2011;18:1044-51
   PubMed Web of Science ®Google Scholar
• Ozkaya E, Cakir E, Kara F, Impact of hot flashes and night sweats on arotid intima-media thickness and bone mineral density among postmenopausal women. Int J Gynaecol Obstet 2011;113(3):235-8
   PubMed Web of Science ®Google Scholar
• Emond JA, Patterson RE, Natarajan L, Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes. Cancer Epidemiol Biomarkers Prev 2011;20:939-45
   PubMed Web of Science ®Google Scholar
• Huang Y, Malone KE, Cushing-Haugen KL, Relationship between menopausal symptoms and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:379-88
   PubMed Web of Science ®Google Scholar
• Writing Group for Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl 1):s1-s66
   PubMed Web of Science ®Google Scholar
• Anderson GL, Limacher M, Assaf AR, Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
   PubMed Web of Science ®Google Scholar
• Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000 – 2009. Menopause 2011;18:385-92
   PubMed Web of Science ®Google Scholar
• Ravdin PM, Cronin KA, Howlader N, The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4
   PubMed Web of Science ®Google Scholar
• Glass AG, Lacey JV Jr, Carreon JD, Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-61
   PubMed Web of Science ®Google Scholar
• Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427-30
   PubMed Web of Science ®Google Scholar
• Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28
   PubMed Web of Science ®Google Scholar
• Eisenberg DM, Kessler RC, Van Rompay MI, Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001;135:344-51
   PubMed Web of Science ®Google Scholar
• Eisenberg DM, Davis RB, Ettner SL, Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-75
   PubMed Web of Science ®Google Scholar
• Gold EB, Bair Y, Zhang G, Cross-sectional analysis of specific complementary and alternative medicine (CAM) use by racial/ethnic group and menopausal status: the Study of Women's Health Across the Nation (SWAN). Menopause 2007;14:612-23
   PubMed Web of Science ®Google Scholar
• Mahady GB, Parrot J, Lee C, Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003;10:65-72
   PubMed Web of Science ®Google Scholar
• Bair YA, Gold EB, Zhang G, Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women's Health Across the Nation. Menopause 2008;15:32-43
   PubMed Web of Science ®Google Scholar
• Cvoro A, Paruthiyil S, Jones JO, Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology 2007;148:538-47
   PubMed Web of Science ®Google Scholar
• Mersereau JE, Levy N, Staub RE, Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol 2008;283:49-57
   PubMed Web of Science ®Google Scholar
• Evans RM. The steroid and thyroid hormone receptor superfamily. Science (New York, NY) 1988;240:889-95
   Google Scholar
• Webb P, Lopez GN, Uht RM, Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-56
   PubMed Web of Science ®Google Scholar
• Feng W, Ribeiro RC, Wagner RL, Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998;280:1747-9
   PubMed Web of Science ®Google Scholar
• McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44
   PubMed Web of Science ®Google Scholar
• An J, Ribeiro RC, Webb P, Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci USA 1999;96:15161-6
   PubMed Web of Science ®Google Scholar
• Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999;20:358-417
   PubMed Web of Science ®Google Scholar
• Krege JH, Hodgin JB, Couse JF, Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95:15677-82
   PubMed Web of Science ®Google Scholar
• Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev 2007;28:575-87
   PubMed Web of Science ®Google Scholar
• Hammes SR, Levin ER. Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 2011;152:4489-95
   PubMed Web of Science ®Google Scholar
• Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev 2007;28:726-41
   PubMed Web of Science ®Google Scholar
• Paruthiyil S, Cvoro A, Zhao X, Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PloS One 2009;4:e6271
   PubMedGoogle Scholar
• Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002;143:4172-7
   PubMed Web of Science ®Google Scholar
• Minutolo F, Macchia M, Katzenellenbogen BS, Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 2011;31:364-442
   PubMed Web of Science ®Google Scholar
• Paruthiyil S, Parmar H, Kerekatte V, Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-8
   PubMed Web of Science ®Google Scholar
• Zhang L, Blackman BE, Schonemann MD, Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons. PloS One 2010;5:e11791
   PubMed Web of Science ®Google Scholar
• Kupfer R, Swanson L, Chow S, Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101. Drug Metab Dispos 2008;36:2261-9
   PubMed Web of Science ®Google Scholar
• Grady D, Sawaya GF, Johnson KC, MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 2009;16:458-65
   PubMed Web of Science ®Google Scholar
• Tagliaferri M, Creasman J, Caygill KA, Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101. Climacteric 2012. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Heldring N, Pike A, Andersson S, Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87:905-31
   PubMed Web of Science ®Google Scholar
• Shughrue PJ, Askew GR, Dellovade TL, Estrogen-binding sites and their functional capacity in estrogen receptor double knockout mouse brain. Endocrinology 2002;143:1643-50
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7:310-17
   PubMed Web of Science ®Google Scholar